Diana Lüftner, Hans-Christian Kolberg, Andreas D. Hartkopf, Tanja N. Fehm, Manfred Welslau, Volkmar Müller, Florian Schütz, Peter A. Fasching, Christian Jackisch, Frederik Marme, Katharina Keller, Manuel Hörner, Chloë Goossens, Erik Belleville, Michael Untch, Marc Thill, Hans Tesch, Nina Ditsch, Julia C. Radosa, Maggie Banys-Paluchowski, Achim Wöckel, Nadia Harbeck, Elmar Stickeler, Rupert Bartsch, Bahriye Aktas, Andreas Schneeweiss, Johannes Ettl, Florin-Andrei Taran, Wolfgang Janni, Rachel Würstlein, Michael P. Lux
- The use of CDK4/6 inhibitors, the new PI3K/AKT-kinase inhib-
itors, selective estrogen receptor-degraders (SERDs), anti-
body-drug conjugates, immune therapies and PARP inhibitors
in recent years has resulted in a marked change in the therapy
landscape for patients with advanced stage breast cancer.
CDK4/6 inhibitors, trastuzumab deruxtecan, and sacituzumab
govitecan have all been shown to provide significant overall
survival benefits compared to conventional chemotherapy.
Other substances are also showing promising results and hold
out the hope that further analysis of the overall survival bene-
fits will be available in the near future. The speed at which
studies are now being carried out has markedly increased,
and conferences and specialist journals are now constant
sources of new information. This review summarizes the most
recent publications and conference presentations on the
treatment of patients with advanced stage breast cancer
